MBX Biosciences will hold a virtual investor event on June 12, 2026, to discuss presentations of once-weekly canvuparatide at the Endocrine Society’s Annual Meeting (ENDO 2026). The company will present one-year extension data and full 12-week Phase 2 trial results of canvuparatide, a treatment for chronic hypoparathyroidism. Management and key scientific advisors will discuss the data and future development plans. The webcast will be accessible live and archived on MBX's investor website.
Entrada Therapeutics announced that an independent Data Monitoring Committee has recommended increasing the dose to 10 mg/kg for Cohort 2 in its ELEVATE-45-201 Phase 1/2 trial for Duchenne muscular dystrophy. This follows safety and pharmacokinetic r...
Herantis Pharma telah menerima tanggapan positif dari FDA AS mengenai desain studi Fase 2a untuk HER-096, kandidat utama mereka untuk pengobatan penyakit Parkinson. FDA tidak memiliki kekhawatiran mengenai informasi kimia, manufaktur, dan kontrol (CM...
ISTO announced the creation of the PNT Standards Consortium, a nonprofit group formed by Leidos, IS4S, and TRX Systems to advance open, interoperable standards for Positioning, Navigation, and Timing (PNT) systems. The consortium aims to provide long...
Cardinal Infrastructure Group announced the acquisition of Piedmont Pipe Construction, a leading wet utilities provider in North and South Carolina. This move expands Cardinal's wet utility capabilities in the growing Charlotte, NC market and integra...
YieldMax® has declared monthly distributions for its Target 12™ ETFs, aiming for a 12% annual income. The ETFs include BIGY, RNTY, and SOXY, each with varying distribution rates and risks such as price participation limits and liquidity concerns. Inv...
